AI startup Lunit has received the approval of Singapore’s Health Sciences Authority to commercialise its AI diagnostic tools for analysing chest x-ray and breast mammography.
WHAT THEY DO
Both AI products are under the Lunit INSIGHT product line. According to a press statement, the Lunit INSIGHT CXR and INSIGHT MMG provide lesion detection with around 96-99% accuracy and visualise the location of x-ray findings.
The Lunit INSIGHT products are being used in over 300 sites globally and have secured CE marks for commercialisation in Europe and approvals in more than 30 countries, such as Japan and Australia.
WHY IT MATTERS
Lunit recognises Singapore as the healthcare hub of the Asia-Pacific region where there is “high quality and easy” access to medical services. Its breast screening tool has been already applied to FeM Surgery, one of the island city state’s largest healthcare providers.
THE LARGER TREND
In July, Lunit scored a $26 million investment from Guardant Health, a Nasdaq-listed precision oncology firm, during a Series C Tranche B funding round. The company also announced its upcoming partnership with an unnamed liquid biopsy company.
In other news, Fujifilm’s AI-powered chest x-ray software CXR-AID, which runs on Lunit INSIGHT CXR, was recently cleared for commercial release in Japan. With the Lunit AI tool, the software can detect 10 of the most common findings in a chest x-ray.